First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors.
D. Strumberg
Consultant or Advisory Role - Bayer; Boehringer Ingelheim (U); Lilly; Pfizer; Roche
Honoraria - Bayer; Boehringer Ingelheim; Lilly; Pfizer; Roche
B. Schultheis
No relevant relationships to disclose
U. Traugott
Consultant or Advisory Role - Silence Therapeutics
C. Vank
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
A. Santel
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
O. Keil
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
K. Giese
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
J. Kaufmann
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
J. Drevs
Consultant or Advisory Role - Silence Therapeutics